Drug intelligence / Profile preview

CBT005

Development stage: Preclinical
Lead developer: Kannavis Biotech
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

CBT005 is a preclinical-stage cancer therapeutic candidate being developed by CanBas Co. Ltd. It is described as a cancer immune-related fusion compound that utilizes a specialized drug delivery system (DDS). The program is designed to leverage immune-modulating components to enhance the body's anti-tumor response. As of 2024, the specific molecular target of CBT005 remains undisclosed by the sponsor, and the drug is currently undergoing preclinical study preparation to support future clinical trials.

Targets

TLR (Toll-like receptors)

Beyond the preview

Go deeper on CBT005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CBT005.

Explore the full profile